EP4702007A1 - Verfahren zur intravenösen tryptaminverabreichung zur behandlung, vorbeugung und/oder linderung von depression - Google Patents

Verfahren zur intravenösen tryptaminverabreichung zur behandlung, vorbeugung und/oder linderung von depression

Info

Publication number
EP4702007A1
EP4702007A1 EP24775626.5A EP24775626A EP4702007A1 EP 4702007 A1 EP4702007 A1 EP 4702007A1 EP 24775626 A EP24775626 A EP 24775626A EP 4702007 A1 EP4702007 A1 EP 4702007A1
Authority
EP
European Patent Office
Prior art keywords
dmt
dose
salt
solvate
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24775626.5A
Other languages
English (en)
French (fr)
Inventor
Deepak Cyril D SOUZA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of EP4702007A1 publication Critical patent/EP4702007A1/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP24775626.5A 2023-03-21 2024-03-20 Verfahren zur intravenösen tryptaminverabreichung zur behandlung, vorbeugung und/oder linderung von depression Pending EP4702007A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363453709P 2023-03-21 2023-03-21
PCT/US2024/020704 WO2024197022A1 (en) 2023-03-21 2024-03-20 Intravenous dimethyltryptamine (dmt) administration method for treating, preventing, and/or ameliorating depression

Publications (1)

Publication Number Publication Date
EP4702007A1 true EP4702007A1 (de) 2026-03-04

Family

ID=92842658

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24775626.5A Pending EP4702007A1 (de) 2023-03-21 2024-03-20 Verfahren zur intravenösen tryptaminverabreichung zur behandlung, vorbeugung und/oder linderung von depression

Country Status (2)

Country Link
EP (1) EP4702007A1 (de)
WO (1) WO2024197022A1 (de)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024512796A (ja) * 2021-04-01 2024-03-19 テラン バイオサイエンシーズ インク． サイケデリック薬およびセロトニン受容体調節因子に関する方法と組成物
EP4366729A4 (de) * 2021-07-07 2025-06-11 Arcadia Medicine, Inc. Sicherere psychoaktive zusammensetzungen
US20230346718A1 (en) * 2022-04-27 2023-11-02 Yale University Method of treating, ameliorating and/or preventing depression

Also Published As

Publication number Publication date
WO2024197022A1 (en) 2024-09-26

Similar Documents

Publication Publication Date Title
AU2021267101B2 (en) MDMA treatment to enhance acute emotional effects profile of LSD, psilocybin or other psychedelics
AU2021227523B2 (en) Controlling effects after 5HT2A agonists administration
Hüter et al. Low-dose intravenous midazolam reduces etomidate-induced myoclonus: a prospective, randomized study in patients undergoing elective cardioversion
EP1793671B1 (de) Verwendung von memantin (namenda) zur behandlung von autismus, zwangsverhalten und impulsivität
Rauser et al. Effect of medetomidine‐butorphanol and dexmedetomidine‐butorphanol combinations on intraocular pressure in healthy dogs
US12465583B2 (en) Methods of treatment using an mTORC1 modulator
Ernst et al. Intravenous dextroamphetamine and brain glucose metabolism
Hommer et al. The effect of orally administered dronabinol on optic nerve head blood flow in healthy subjects—A randomized clinical trial
US20230346718A1 (en) Method of treating, ameliorating and/or preventing depression
Song et al. Psilocybin to promote synaptogenesis in the brains of patients with mild cognitive impairment
EP4702007A1 (de) Verfahren zur intravenösen tryptaminverabreichung zur behandlung, vorbeugung und/oder linderung von depression
EP3454853B1 (de) Behandlung von alkoholismus und depression unter verwendung von ibudilast
CN112822997A (zh) 用于治疗孤独症的组合物和方法
JP2021530568A (ja) 自閉症を処置するための組成物および方法
Wilkins et al. Alternative to ganglionic blockade with anticholinergic and alpha-2 receptor agents
JP2008536921A (ja) アルコール及び／又は刺激物質の乱用を治療するための選択的塩素イオンチャネルモジュレーターの使用
Iida et al. Effects of alcohol infusion on smoking-induced cerebrovascular changes in rat in vivo
Hensel et al. Rapid Opiate Detoxification Under General Anesthesia: A New Challenge for Anesthesiologists and Intensivists
Straneva Use of certain pharmacological agents influences cardiovascular and neuroendocrine responses to stress
Agrawal Comparison of IV dexmedetomidine vs Midazolam during Tympanoplasty procedure under MAC
DATE Investigator’s Brochure
Postma An experimental and functional neuroimaging investigation into the effects of nicotine on prepulse inhibition of the startle reflex in schizophrenia

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20260102

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR